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Abstract The aim of this study was to verify if low-level laser
therapy could be useful to reduce chemotherapy-related oral
mucositis grading and pain in childhood undergoing chemo-
therapy. A randomized double-blind clinical trial was carried
out. Patients from 3 to 18 years of age undergoing cancer
therapy and presenting OM grade 2 or more were eligible
for this study. Patients were randomly divided in two groups:
group A received laser therapy from the day of OM diagnosis
and other 3 consecutive days (830 nm wavelength, power
150 mW, spot size 1 cm2, 30 s per cm2, energy density
4.5 J/cm2); group B received sham therapy (placebo) with
the same timing. Two blind clinicians performed OM scoring
and pain evaluation at day 1 (immediately before the begin-
ning of laser treatment—T0), day 4 (after finishing laser ther-
apy cycle—T1) and at day 7 (T2) as follow-up. A total of 123
patients were included in the study. Group Awas composed of
62 children while group B is 61; in both groups, there was a
progressive reduction in grade of OM, and at day 7, not every
mucosal lesion disappeared. The difference in the decline of
OM grading between the two groups resulted not statistically
significant (p = 0.07). A statistically significant difference in
pain reduction between two groups both at T1 and at T2
(p < 0.005) was observed. This study demonstrated the
efficacy of LLLT in reducing pain due to chemotherapy-
induced oral mucositis in children, while no significant benefit
was noted in reducing OM grade.
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Introduction
Although the effectiveness of anti-cancer treatment in children
has continued to improve over the past decades, collateral
damage to the head and neck structures are frequently reported
[1].
Oral mucositis (OM) is a common side effect of chemo-
therapy, especially in the case of haematopoietic stem cell
transplantation (HSCT) due to the high dose of myeloablative
chemotherapy used for conditioning regimens with an inci-
dence in the paediatric cancer population of 50 to 80 % [2, 3].
OM reduces the ability to consume adequate nutrients and
limits food intake, due to pain and discomfort when patients
swallow or chew. Therefore, it increases the risk of malnutri-
tion and impairs the quality of life.
In addition, ulcers in immunocompromised children can be
the gateway for microorganisms, which can cause local and
systemic infections [4].
Current management of OM might comprise growth fac-
tors and cytokines, anti-inflammatory agents, anaesthetics, an-
algesics, antimicrobial and coating agents, cryotherapy and
mucosal protectants, such as zinc [5, 6]. In addition, oral care
protocols are suggested to be used to prevent oral mucositis in
all age groups and across all cancer treatment modalities.
Among the current topical therapies, 2 % morphine mouth-
wash and 0.5 % doxepin mouthwash may be effective to treat
pain due to OM, while sucralfate mouthwash and chlorexidine
mouthwash are not recommended to treat chemotherapy-
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induced OM [5]. In children, apart from oral care protocols,
only weak recommendations are available to prevent and to
reduce the severity of cancer related OM; in particular, the
literature suggests cryotherapy, keratinocyte growth factor
(KGF) and low-level light therapy to treat oral mucositis [7].
The last update of the guidelines for the management of
mucositis secondary to cancer therapy recommends the use of
low-level laser therapy (LLLT) for the prevention of OM in
patients receiving HSCT conditioning high-dose chemothera-
py, to reduce OM severity and pain [5]. In addition, recent
studies recommend including photo medicine using LLLT as
a possible way of prophylactic and therapeutic intervention in
the management protocol of OM in adult cancer patients, in
order to prevent and reduce duration and severity of OM and
associated pain [8]. Guidelines for photobiomodulation
(PBM) are still not possible in cancer children, but a recent
study ruled on a children population undergoing chemothera-
py states that laser therapy, even if conducted through daily
section, was fast, well tolerated, feasible and affordable [9,
10]. In addition, all the papers focusing on LLLT in cancer
children reported a positive feedback from patients and care-
givers [4, 11]. On the other hand, since LLLT should be exe-
cuted with full oral care protocols and incorporated into the
routines of the children, it requests an intense participation of
patients’ caregivers and a multidisciplinary staff including
dentists and oral hygienists [12].
LLLT seems to have three main effects: analgesic, anti-
inflammatory and wound-healing properties [13, 14].
The mechanism through which the laser interacts with bi-
ological tissues seems to modulate various metabolic process-
es, by conversion of the laser light energy input into energy
useful to cells [15]. Visible laser is absorbed by primary
ENROLMENT
New accesses in paediatric 
hemato-oncologic unit 2012-2013 
Paents receiving 
chemotherapy (n=875) 
Excluded (n=77).  Non 
CT paents 
Analysed (n=123) 
Excluded from analysis 
(not signed informed 
consent) (n=3) 
Excluded from analysis 
(worsening health condion: 
infecons, recurrent 
tumour, trismus) (n=13) 
Excluded from analysis  
(paents receiving 
radiotherapy) (n=142) 
Paents with OM 
(n=393) 
Excluded from analysis (not meeng 
enrollment criteria: reduced mouth 
opening (<1 cm), dysplasc oral 
lesions, head and neck RT (n=112) 
(n=952)
Fig. 1 Diagram demonstrating
the flow of participants during
enrolment stage
Table 1 Demographic
characteristics of the patients Group A (n = 62) Group B (n = 61) p value
Male–female 43.5 % (n = 27) 47.5 % (n = 29) 0.65
Age 9.8 ± 3.25 9.27 ± 3.85 0.41
Disease
Leukemia and lymphoma 38 34
Solid tumours 6 7
HSCT 18 20
Mean ± SD; test: t Student, p value < 0.05
HSCT hemopoietic stem cell transplantation
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photoacceptors (chromophores) in the mitochondria respirato-
ry chain with an increase in ATP production, cellular prolifer-
ation and protein synthesis, aiding tissue repair, through an
increased vascularity and re-epithelialization. In addition, the
anti-inflammatory and analgesic effect can be linked to the
peripheral endogenous opioid production, a decrease in pro-
inflammatory cytokines, a decrease in free oxygen radicals
and to the alterations in nerve impulse conduction [16–18].
Although in recent years, several papers have focused
attention on the use of LLLT for chemotherapy-induced
OM prevention and treatment in adults, at the best of
our knowledge, there are very few papers examining the
efficacy of this methodology in children undergoing
chemotherapy, with contradictory results. Cruz et al.
2007 [4] found no evidence of benefit from the prophy-
lactic use of LLLT in children undergoing chemotherapy
with optimal dental care; on the contrary, Kuhn et al.
2009 [11] encouraged the use of laser treatment in chil-
dren with chemotherapy-induced OM, as did Moraes
et al. 2009 [19], who experimented OM healing through
extra oral application of LLLT in children.
The aim of this study is to verify the efficacy of LLLT in
reducing the severity and pain of chemotherapy-induced oral
mucositis in childhood.
Methods
Sample selection
This study was carried out from January 2012 to December
2013 at the Paediatric Dentistry Department and at the
Paediatric Oncology Unit of Spedali Civili of Brescia (Italy).
All children between 3 and 18 years of age receiving chemo-
therapy for haematological malignancies, solid tumours or
HSCT and presenting OM grade 2 or greater were eligible
for this study. Patients with reduced mouth opening <1 cm2
not allowing the laser irradiation of soft tissues or with dys-
plastic oral lesions or undergoing head and neck radiation
therapy in the previous 4 weeks were excluded from the study.
Patients were randomized into two groups by a computer
code: group Awas made up of children receiving laser therapy
and group B of patients receiving sham therapy (placebo), i.e.
the device was turned on but the hand piece did not work.
Laser therapy started on day 1 of the diagnosis of OM and
continued for another 3 consecutive days (4 days in total).
Laser therapy was dispensed during hospitalization;
discharged patients continued laser therapy as outpatients,
but no patient with OM >2 was discharged.
Laser equipment
The laser instrument used for this trial was a portable and easy
to handle diode laser (DioBeam 830, CMS Dental,
Copenhagen, Denmark). The laser was applied by a trained
dentist and irradiated in the sites of OM (buccal mucosa, lip
mucosa, tongue, floor of mouth and soft palate), with 830 nm
wavelength, power 150 mW, spot size 1 cm2, 30 s per cm2,
energy density 4.5 J/cm2.
Dentist, patients and caregivers wore appropriate protective
eyewear, following international safety procedures.
DAY 1 DAY 4 DAY 7
GROUP A 
GROUP B 
Fig. 2 Assessment of OM grade
on day 1 (T0), day 4 (T1) and day
7 (T2) in group A and group B
Table 2 Results for decline in VAS at T0, T1 and T2
Group A
(Laser treatment)
Group B
(Sham therapy)
W (Wilcoxon test) p value
T0 4 4 3805.5 0.90
T1 1 2 3252 0.002
T2 0 1 3160.5 0.0005
Medians, Wilcoxon rank sum test and p value. Test: Wilcoxon rank sum
test, p value < 0.05
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OM scoring
Oral mucositis scoring was carried out by the same two pae-
diatric dentists blind to the randomized allocation, according
to the Common Toxicity Criteria Scale of the WHO. Lesions
were classified as grade 0 = none; grade 1 = soreness and ery-
thema; grade 2 = erythema and ulcers without difficulties in
swallowing solid food; grade 3 = ulcers requiring only a liquid
diet and grade 4 = introduction of parental nutrition.
Oral examination and OM scoring were performed on day
1 (immediately before the beginning of laser treatment) (T0),
day 4 (after finishing laser therapy cycle) (T1) and on day 7
(T2) as follow-up.
Dentists who applied the laser did not participate in the
scoring of OM.
Pain scoring
Pain was evaluated through the visual analogue scale (VAS) at
the same time as OM scoring. In this system, 1 indicates no
pain and 10 indicates severe pain; patients were asked to select
a number from 1 to 10 on a ruler with drawn faces to express
the intensity of their pain. Request of additional analgesia, that
means the number of times that children required pharmaco-
logical support in addition to laser therapy, was also reported
in the clinical charts.
Statistical analysis
Statistical analysis was descriptive, including mean, standard
deviation and percentiles for variables such as sex, age and
localization.
To compare the two groups, we analysed the data on gender
and disease as frequencies and percentages. Concordance or
differences in the frequency distribution between the two
groups were tested using the Student t test. A level of signif-
icance of 5 % was used and data were analysed using Stata®
software for Mac. The differences in decline of OM and VAS
score were analysed using the Wilcoxon rank sum test.
Estimating that there is a success percentage of 70 % on
day 7 for the group treated by laser and 40 % for the control
group, the minimum number of patients for the study, assum-
ing alpha 0.05 and beta 0.20 (study power = 80 %), was cal-
culated to be 100 (at least 50 per group).
Ethical considerations
The study was approved by the Ethical Committee of the
Spedali Civili of Brescia (IP =1532), and all patients and their
caregivers were informed about the research and signed an
informed consent.
Results
A total of 123 patients were included in the study according to
the enrolment criteria (Fig. 1). Group A (laser treatment) was
composed of 62 children while group B (sham therapy) of 61.
Demographic characteristics are resumed in Table 1.
OM grading
Oral mucositis appeared at a mean of 5.9 days after the begin-
ning of chemotherapy (range 4 to 8 days).
At T0, the median of OM grading was 3 for group A and 3
for group B (p = 0.80). On the 4th day (T1), OM grading
median was 2 for group A and 2 for group B (p = 0.65); after
7 days (T2), OM grading median resulted 0 in group A and 1
in group B (p = 0.07). In both groups, there was a progressive
reduction in the grade of OM, even if on day 7, not all mucosal
lesions had disappeared. The difference in the decline of OM
grading between the two groups at each interval resulted not
statistically significant (Fig. 2).
Pain evaluation
The medians of VAS at the three intervals and p values ob-
tained by theWilcoxon rank sum test are displayed in Table 2.
VAS values at T1 and T2 were lower in the group A respect of
group B in a statistically significant way (p < 0.05). During the
study period, children treated with laser therapy required less
additional analgesia (paracetamol, tramadol or morphine) with
respect to those belonging to the sham protocol (p < 0.05).
Discussion
With the advancement of technology, the use of laser has been
considered in various areas of medicine and dentistry.
Nowadays, the price of laser devices has considerably de-
creased, making the technology easily available [12].
In the last decade, many papers about the use of LLLT in
the prevention and treatment of cancer therapy-induced mu-
cositis have been published, even if there is a lack of exclusive
paediatric studies. The results reported in previous studies are
often discordant [20, 21]. Cruz et al. 2007 [4], in a paper
focused on a paediatric population receiving chemotherapy
or HSCT, found no benefit in the prevention or reduction of
OM from the prophylactic use of LLLT when optimal dental
care was provided. Similarly, Simoes et al. 2009 [16] did not
find enough information to conclude that LLLT is beneficial
for OM reduction. On the other hand, several papers regarding
children or mixed population demonstrated that LLLT can be
useful in cancer therapy-OM reduction and in the decreasing
of OM related pain [11, 19, 22–25].
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The results of the present trial in childhood partially con-
firm the findings of previous studies, both in adults and in
children [22, 26–31]; the duration and the grading of OM
was not actually significantly different in the group treated
by laser vs sham therapy, but a statistically significant differ-
ence in pain reduction between the two groups was observed,
both from VAS scale results and from request of additional
analgesia. A decrease in pain should be attributed to the prop-
erties of the laser technology itself, which selectively inhibits
the nociceptive signal arising from peripheral nerves, blocking
the pain gate [32, 33].
The discrepancy between our findings and others reported
in literature could be explained by the possibility of OM spon-
taneous healing in many cases without complications, espe-
cially if children undergoing cancer therapy are educated to
strictly follow oral hygiene protocols, just as it was for patients
of the present study. In addition, the negative result on the
healing of mucositis could by be a consequence of the laser
protocol chosen in this study; maybe a longer laser treatment
would be more effective [4, 22].
The laser energy level used for this trial was based on
several previous studies, as Migliorati et al. 2013;
Bensadoun and Nair 2012 [8, 34] defined the energy density
for laser therapeutic use at least 4 J/cm2.
However, in literature, it is still not clear what specific
extent in wavelength is meaningful in terms of light-tissue
interaction, even if it is now demonstrated that wavelengths
between 632 and 830 nm can be beneficial for preventing and
treating OM [34]. In a previous report, Schubert et al. 2007
[28] found that wavelength of 650 nm produced better results
than 780 nm in the prevention of oral mucositis.
This study reported that there was no difference in the
reduction of oral mucositis between the two groups, but only
in the pain amelioration. The slight contrast with other studies
[37] may be partially explained by the wavelengths used. In
fact, we chose a high wavelength (830 nm) in order to verify
if, exploiting the spectra absorption of cytochrome c oxidase,
which is about 825 nm, and increasing the cellular metabolism
and the oral mucosa healing process [35, 36], this type of
wavelengths could be an alternative to 632–660 nm laser
lights.
It is known that oral mucositis derive from complex
mechanisms in both mucosal epithelial tissues and
subepithelial tissues; then, different wavelengths act on
different targets at different levels. In particular, 632 to
660 nm light works on superficial layers and on epithe-
lial tissues, and 780 to 901 nm penetrates much deeper
in the subepithelial tissues. Schubert et al. 2007 demon-
strated in a study [28] that shorter wavelengths would
be more effective in preventing mucositis in patients
undergoing haematopoietic cell transplantation, because
632–660-nm laser releases most of its energy in the
superficial layers. On the contrary, Cauwels et al. 2011
[31] obtained positive results in oral mucositis healing
with a 830-nm wavelength.
Although the ideal laser wavelength has not been yet well
defined, the results of this and other papers seem to lead to the
conclusion that it is advisable to prefer lower wavelengths
(632–660 nm) to obtain oral mucositis healing, in addition
to pain relief.
Neutrophil serological levels and different chemotherapy
protocols are possible confounders that could affect laser ther-
apy outcome; not having discussed them in this trial could
represent a weak point of this study.
On the contrary, a strong point of this research is the
double-blind randomized design, focused on an exclusive pae-
diatric population and carried out by trained staff; the number
of patients in the two groups is representative and larger than
other previous reports.
This study has demonstrated the efficacy of LLLT in
reducing pain due to chemotherapy-induced oral mucosi-
tis. The lack of a unique, standardized protocol for using
laser therapy in treatment of OM and relief pain is to be
noted; however, further randomized controlled trials with
different laser application schedules in children are still
needed.
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